April 2024 - World School of Life Sciences IP

Complex Landscape of Xarelto® in the EU: A Comprehensive Overview

Tanu Goyal April 19, 2024

Rivaroxaban, marketed under the brand name Xarelto®, has emerged as a pivotal therapeutic option for various cardiovascular conditions, revolutionizing the landscape of anticoagulant therapy. Its

Approved Agreement Allowed Validation Concept

Denosumab first interchangeable biosimilars approved by the US FDA

Tanu Goyal April 17, 2024

With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count

New rules for implementing China patent law and guidelines for re-examination

Tanu Goyal April 2, 2024

The final versions of the updated Guidelines for Patent Examination and the Implementing Rules for the Patent Law were released by the China National Intellectual

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.